<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01635972</url>
  </required_header>
  <id_info>
    <org_study_id>9766-CL-0044</org_study_id>
    <nct_id>NCT01635972</nct_id>
  </id_info>
  <brief_title>Drug Interaction Study of Multiple Doses of Isavuconazole and a Single Dose of Bupropion</brief_title>
  <official_title>A Phase 1, Open-Label Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Bupropion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Global Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Basilea Pharmaceutica International Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of multiple doses of isavuconazole on the
      pharmacokinetics of a single dose of bupropion.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) profile for bupropion (in plasma): AUCinf, AUClast, Cmax</measure>
    <time_frame>Day 1 at pre-dose and 0.5,1,1.5, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 48, 72,and 96 hours post-dose and Day 15 at pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,10,12,16, 20, 24, 48, 72, 96,120, and 144 hours post-dose</time_frame>
    <description>Area under the concentration-time curve (AUC) from time 0 extrapolated to infinity (AUCinf), AUC from time of dosing to the last quantifiable concentration (AUClast), and maximum concentration(Cmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK profile for bupropion (in plasma): t1/2, tmax, CL/F, and Vz/F</measure>
    <time_frame>Day 1 at pre-dose and 0.5,1,1.5, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 48, 72,and 96 hours post-dose and Day 15 at pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,10,12,16, 20, 24, 48, 72, 96,120, and 144 hours post-dose</time_frame>
    <description>Apparent terminal elimination half-life (t1/2), Time to attain Cmax (tmax), Apparent body clearance after oral dosing (CL/F), and apparent volume of distribution (Vz/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile for hydroxybupropion (in plasma): AUCinf, AUClast, Cmax, t1/2, tmax</measure>
    <time_frame>Day 1 at pre-dose and 0.5,1,1.5, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 48, 72,and 96 hours post-dose and Day 15 at pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,10,12,16, 20, 24, 48, 72, 96,120, and 144 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile for Isavuconazole (in plasma): AUCtau, Cmax, and tmax</measure>
    <time_frame>Days 14 and 15 at pre-dose and 0.5,1,1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 20 hours post-dose</time_frame>
    <description>AUC during time interval between consecutive dosing (AUCtau)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Isavuconazole (in plasma): trough concentration (Ctrough)</measure>
    <time_frame>Pre-dose on Days 10 through 13 and Days 16 through 19 and on Day 20: predose and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by recording of adverse events, clinical laboratory evaluation, electrocardiograms (ECGs) and vital signs</measure>
    <time_frame>Days 1 through 27 (Â± 2 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Pharmacokinetics of Isavuconazole</condition>
  <condition>Pharmacokinetics of Bupropion</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Isavuconazole and bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bupropion hydrochloride on Days 1 and 15, Isavuconazole three times per day (TID) on Days 8 and 9, and once daily (QD) on Days 10 thru 20.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isavuconazole</intervention_name>
    <description>oral</description>
    <arm_group_label>Isavuconazole and bupropion</arm_group_label>
    <other_name>BAL8557</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupropion hydrochloride</intervention_name>
    <description>oral</description>
    <arm_group_label>Isavuconazole and bupropion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject has a body weight of at least 45 kg and a body mass index of 18 to 32
             kg/m2, inclusive

          -  The subject's clinical laboratory test results at Screening and Day 1 are within
             normal limits unless the Investigator considers the abnormality to be &quot;not clinically
             significant.&quot; Results for aspartate aminotransferase (AST), alanine aminotransferase
             (ALT), and total bilirubin must not be above the normal range

          -  Subject agrees to sexual abstinence, or is surgically sterile, or is using a medically
             acceptable double barrier method to prevent pregnancy during the study and for three
             weeks after the follow up phone call at the end of the study, or, if female, is
             postmenopausal

        Exclusion Criteria:

          -  The subject has a history of unexplained syncope, cardiac arrest, unexplained cardiac
             arrhythmia or torsade de pointes, structural heart disease, or family history of Long
             QT syndrome (suggested by sudden death of a close relative at a young age due to
             possible or probable cardiac causes)

          -  The subject has/had a symptomatic, viral, bacterial (including upper respiratory
             infection), or fungal (non-cutaneous) infection within 1 week prior to clinic
             admission on Day -1

          -  The subject has a positive result for hepatitis B surface antigen or hepatitis C
             antibodies at Screening or is known to be positive for human immunodeficiency virus

          -  The subject has a known or suspected allergy to any of the components of the trial
             products or the azole class of compounds, or a history of multiple and/or severe
             allergies to drugs or foods (as judged by the Investigator), or a history of severe
             anaphylactic reactions

          -  The subject is a smoker (any use of tobacco or nicotine containing products) in the
             last 6 months

          -  The subject has had treatment with prescription drugs or complementary and alternative
             medicines within 14 days prior to Day -1, or over-the-counter medication within 1 week
             prior to Day -1, with the exception of acetaminophen up to 2 g/day

          -  The subject has received an experimental agent within 30 days or 5 half-lives,
             whichever is longer, prior to Day -1

          -  The subject has a history of suicidal behavior and/or ongoing suicidal ideation as
             assessed using C-SSRS (Columbia - Suicide Severity Rating Scale) at Screening or at
             Clinic Check-In (any response of &quot;yes&quot; to the Suicidal Ideation questions on the
             C-SSRS)

          -  The subject has a current or past history of seizure disorder or epilepsy

          -  The subject has a current or past history of depression, anorexia nervosa or bulimia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Phama Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2012</study_first_submitted>
  <study_first_submitted_qc>July 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2012</study_first_posted>
  <last_update_submitted>August 31, 2015</last_update_submitted>
  <last_update_submitted_qc>August 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Isavuconazole</keyword>
  <keyword>Bupropion</keyword>
  <keyword>Bupropion hydrochloride</keyword>
  <keyword>Healthy Volunteers</keyword>
  <keyword>BAL8557</keyword>
  <keyword>BAL4815</keyword>
  <keyword>BAL8728</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

